Aquestive Therapeutics, Inc. AQST Royalty expense
Royalty expense at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty expense?
- Aquestive Therapeutics, Inc. (AQST) reported royalty expense of $973K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s royalty expense changed year-over-year?
- Aquestive Therapeutics, Inc.'s royalty expense decreased by 32.3% year-over-year, from $1.44M to $973K.
- What does royalty expense mean?
- This metric captures the costs associated with payments made to third parties for the right to use intellectual property, patents, or proprietary technologies. It reflects the financial impact of licensing agreements necessary to support the company's product portfolio. High royalty expenses may indicate a reliance on external innovation or specific contractual obligations that impact operating margins.